Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 66.0%

Neg 66% Neu 0% Pos 0%

Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.